- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Ajooni Biotech Limited has announced a board meeting on the amendment of the Capital Clause in its Memorandum of Association, which has been approved by shareholders. The authorised share capital will now be ₹50 crore, divided into 25 crore equity shares with a face value of ₹2 each. This increase in capital can enhance the company’s ability to raise funds and potentially support strategic growth initiatives. Investors might view this move positively, as it positions the company for future opportunities while reflecting confidence in its long-term prospects.